Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

6.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
6.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering T cells with a novel PD-L1-specific TCR targeting immune and cancer cells.

Signal transduction and targeted therapy·2026
Same author

Translational bioinformatics stalls at implementation.

Briefings in bioinformatics·2026
Same author

Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond.

Signal transduction and targeted therapy·2026
Same author

Immune reconstitution in patients with myelofibrosis conditioned with a non-myeloablative regimen prior to allogeneic stem cell transplantation.

Bone marrow transplantation·2026
Same author

Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates.

Signal transduction and targeted therapy·2026
Same author

CD19 exon 2 skipping is a potential prognostic correlate of anti-CD19 CAR-T therapy relapse.

Frontiers in molecular medicine·2026

Related Experiment Video

Updated: Apr 21, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

8.0K

Bioinformatics for cancer immunotherapy target discovery.

Lars Rønn Olsen1, Benito Campos, Mike Stein Barnkob

  • 1Department of Biology, Bioinformatics Centre, University of Copenhagen, Ole Maaløes Vej 5, 2200, Copenhagen, Denmark, lro@binf.ku.dk.

Cancer Immunology, Immunotherapy : CII
|October 27, 2014
PubMed
Summary
This summary is machine-generated.

This review explores bioinformatics tools to improve cancer immunotherapy by addressing limitations in target selection and design. Computational methods can enhance the discovery of effective cancer targets for better treatment outcomes.

More Related Videos

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

11.9K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Related Experiment Videos

Last Updated: Apr 21, 2026

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

8.0K
Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry
08:30

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

11.9K
Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

1.1K

Area of Science:

  • Immunology
  • Bioinformatics
  • Computational Biology

Background:

  • Cancer immunotherapies have advanced significantly but face limitations in efficacy.
  • Harnessing the immune system for cancer treatment remains a key research area.
  • Existing treatments are hindered by biological and technical challenges in target selection.

Purpose of the Study:

  • To review current limitations in immunotherapy target selection and design.
  • To explore computational methods for streamlining target discovery in bioinformatics pipelines.
  • To suggest strategies for overcoming therapy resistance and ensuring durable tumor control.

Main Methods:

  • Detailed review of bioinformatics tools and databases for immunotherapy target discovery.
  • Focus on three key bottlenecks: antigenic protein cataloging, HLA binder identification, and epitope selection.
  • Application of methods to the tumor antigen HER2 as a case study.

Main Results:

  • Identification of specialized bioinformatics tools for critical stages of target discovery.
  • Demonstration of computational approaches for selecting single- and multi-epitope strategies.
  • Examples illustrating the application of these methods to known tumor antigens.

Conclusions:

  • Bioinformatics analysis pipelines can significantly streamline immunotherapy target discovery.
  • Computational methods offer solutions to enhance therapy efficacy and overcome resistance.
  • Improved target selection and design are crucial for realizing the full potential of cancer immunotherapies.